A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
Study Details
Study Description
Brief Summary
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This is an open-label (patients will know the names of study drugs they receive), single-dose, study that will examine the pharmacokinetics (blood levels) and assess survival and safety of trabectedin in patients with advanced malignancies who either have hepatic (liver) dysfunction or do not have hepatic dysfunction (patients enrolled without hepatic dysfunction will be referred to as the control group). Trabectedin is a drug being developed to treat patients with cancer that will be administered intravenously (i.v.) through a catheter (tube) into a central vein. In addition, dexamethasone, a drug used to prevent nausea and vomiting in chemotherapy patients that may have protective effects on the liver, will be administered to patients before the administration of trabectedin. Patients who complete the treatment phase of the study who in the opinion of the investigator would derive an overall clinical benefit from further treatment with trabectedin will have the opportunity to continue treatment with trabectedin in the optional extension phase. The dose and schedule of trabectedin may be modified by the treating physician in the optional extension phase to be more appropriate for the type of malignancy being treated. A single dose of trabectedin (1.3 mg/m2 in patients in the control group and 0.58 mg/m2 in patients with hepatic dysfunction) will be administered by i.v.infusion over a 3-hour period. The dose of trabectedin may be adjusted if necessary for patients with hepatic dysfunction subsequently enrolled in the study. All patients will be administered dexamethasone 20 mg i.v. (or equivalent) approximately 30 minutes before the administration of trabectedin.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Trabectedin 1.3 mg/m^2 plus Dexamethasone Control group Trabectedin 1.3 mg/m^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin. |
Drug: Trabectedin
Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
Drug: Dexamethasone
Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
|
| Experimental: Trabectedin 0.58 mg/m^2 plus Dexamethasone Hepatic dysfunction group Trabectedin 0.58 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin. |
Drug: Trabectedin
Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
Drug: Dexamethasone
Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
|
Outcome Measures
Primary Outcome Measures
- Pharmacokinetics of trabectedin [At protocol-specified time points for up to 8 days]
Secondary Outcome Measures
- Number of patients with adverse events [Up to 30 days after the administration of trabectedin]
- Findings from clinical laboratory evaluations [Up to 30 days after the administration of trabectedin]
- Findings from vital signs measurements [Up to 30 days after the administration of trabectedin]
- Findings from physical examinations [Up to 30 days after the administration of trabectedin]
- Evaluate survival data [at a time point to be determined by the sponsor at a later date.]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with locally advanced or metastatic disease, any solid tumor except hepatocellular carcinoma, who have been previously treated with systemic chemotherapy (chemotherapy administered through the blood) and who have had relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment, or intolerant to prior standard of care treatment with chemotherapy
-
Patients with Eastern Cooperative Oncology Group (ECOG) score of <=2 at the time of screening
-
Patients enrolled with hepatic dysfunction must have laboratory test results for total bilirubin of >1.5x to <=3x the upper limit of normal (ULN) and liver function tests (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) of <8x the ULN
-
Patients enrolled without hepatic dysfunction must have laboratory test results for total bilirubin of less than the ULN, alkaline phosphatase (ALP) <=1.5x the ULN, and AST and ALT of <=the ULN.
Exclusion Criteria:
-
Patients with previous exposure to trabectedin
-
Patients with known liver disease
-
Patients diagnosed with hepatocellular carcinoma, or who have a history of biliary sepsis within the past 2 years
-
Patients unwilling to have a central catheter
-
In hepatic dysfunction group, patients with hepatic dysfunction who have Gilbert's syndrome. Patients signs of encephalopathy (altered brain function).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Scottsdale | Arizona | United States | ||
| 2 | Detroit | Michigan | United States | ||
| 3 | New York | New York | United States | ||
| 4 | Philadelphia | Pennsylvania | United States | ||
| 5 | Salt Lake City | Utah | United States | ||
| 6 | Tacoma | Washington | United States | ||
| 7 | Edegem | Belgium | |||
| 8 | Wilrijk | Belgium | |||
| 9 | Edmonton | Alberta | Canada | ||
| 10 | Barcelona | Spain | |||
| 11 | Madrid | Spain |
Sponsors and Collaborators
- Janssen Research & Development, LLC
- PharmaMar
Investigators
- Study Director: Janssen Research & Development, LLC C. Clinical Trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- CR017542
- ET7430OVC1004